ENDPOINTS

Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugs

Plus, news about Idorsia, Enveda, Zymeworks, BerGenBio and Ignota Labs: Harbour BioMed does another deal: The Shanghai-based biotech’s subsidiary, called HBM Alpha Therapeutics, inked a pact with an undisclosed company for up to

Feb 26, 2025 - 16:30
 0
Harbour BioMed inks deal up to $395M; ORIC refines plans for two drugs
Plus, news about Idorsia, Enveda, Zymeworks, BerGenBio and Ignota Labs: Harbour BioMed does another deal: The Shanghai-based biotech’s subsidiary, called HBM Alpha Therapeutics, inked a pact with an undisclosed company for up to
Read More

Tags:

Previous Article

This Lego Star Wars Millennium Falcon set is 13% off — almost its lowest-ever price

Next Article

Which type of note-taking is better for learning: laptop or pen and paper?

Related Posts

In single case, spinal muscular atrophy pill given before birth spared baby of symptoms

In single case, spinal muscular atrophy pill given befo...

Feb 20, 2025  0

Biotech is still trying to make CRISPR a success

Biotech is still trying to make CRISPR a success

Feb 19, 2025  0

Achira raises $33M Nvidia-backed seed round, blending AI and physics in biotech

Achira raises $33M Nvidia-backed seed round, blending A...

Feb 21, 2025  0